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The Reality and The World
The term “real-world” was coined in the early 1960s
and refers to the realm of practical or actual experi-
ence, as opposed to an abstract, theoretical, virtual, or
idealized world. In our everyday “real-world” prac-
tice, we not so rarely feel a tugging between evi-
dence from some (idealized?) randomized controlled
trials (RCT) and the clinical application of their re-
sults to the speciﬁc patient that we have in front
of us. That is what several of our colleagues named
the difference between “evidence-based” and “patient-
based” medicine. In the practice of interventional
cardiology, this feeling is even more manifest regard-
ing the “ﬁrst-generation” drug-eluting stents (DES)—
namely, sirolimus (SES)- and paclitaxel (PES)-eluting
stents. Without any doubt, these ﬁrst DES revolution-
ized the intervention world by making it possible to
treat millions of people worldwide virtually perfectly.
“Virtually perfectly” because, as noticed since the end
of 2003, the reality of the extended use of DES wowed
the actual vulnerable DES Achilles heel: an increased
occurrence of device-mediated myocardial infarction
due to late stent thrombosis. You all know this story
well and we will not reiterate the details. However,
one should realize that this true complication was
rare enough that RCTs—even those performed in all-
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comers—were clearly underpowered and had follow-
up too soon after surgery to detect the problem.
The Reality and the First-Generation DES
From the intense scrutiny initiated since the 2006
ﬁrestorm,1 we have learned more: First, that DES are
associated with primary late stent thrombosis with a
yearly incidence estimated at 0.5%.2 Second, this is
balanced against the reduced need for revasculariza-
tion compared to bare metal stents (BMS). Third, the
global safety proﬁles of ﬁrst-generation DES are iden-
tical or even better than BMS with no difference in
the overall risk of mortality. But ﬁnally, we learned
something even more essential: Large real-world reg-
istries (such as the Bern-Rotterdam2 or the Dartmouth
Hospital Dynamic Registry published in this edition3)
still belong to the current armamentarium of clinical
research and that only trials with long-term follow-up
are able to detect and circumscribe rare problems, such
as late stent thrombosis.
Several RCTs directly compared the PES with the
SES in all-comers, but few studies report a clinical
follow-up of longer than 1 year. Only Danish Organi-
zation on Randomized Trials With Clinical Outcome
(SORT-OUT II—2,098 patients, maximum follow-up:
18months),4 TAXi (202 patients, maximum follow-up:
36 months)5 and Sirolimus-Eluting Stent Compared
With Paclitaxel-Eluting Stent for Coronary Revascu-
larization (SirTax—1,012 patients, maximum follow-
up: 60months)6 have reported such extended follow-up
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Table 1. Prospective, Open-Label, Randomized Clinical Trials (RCTs) Directly Comparing SES with PES
Studies on SES/PES
Studies on CIN Dartmouth
Hospital
Feldkamp SORT-OUT Dynamic
ICON VALOR CARE RECOVER et al. II TAXi Registry
Patient type Chronic renal
failure
Chronic renal
failure
Chronic renal
failure
Chronic renal
failure
All-comers All-comers All-comers All-comers
No. of patients 71/74 156/143 210/204 140/135 105/116 1,033/1,065 100/102 1012/1332
Diabetics 42%49% 52%/52% 44%/38% 34%/36% 40%/35% 13.9%/14.6% 36%/33% 28%/29%
%PCI 67%/65% N.A. 39%/40% 44%/38% N.A. 100% 100% 100%
Contrast
media
Iodixanol/
Iopromid
Iodixanol/
Ioversol
Iodixanol/
Iopamidol
Iodixanol/
Ioxaglate
Iodixanol/
Ioxaglate
N.A. N.A. N.A.
Mean contrast
use (mL)
215/204 118/130 136/134 205/195 N.A. 159/157 139 ± 13 304/311
CIN deﬁnition SCr ↑ >0.5
mg/dL or
>25%
SCr ↑ >0.5
mg/dL
SCr ↑ >0.5
mg/dL
SCr ↑ >0.5
mg/dL or
>25%
SCr ↑ >25% N.A. N.A. SCr ↑ >25%
Incidence of
CIN (%)
16%/24% 22%/24% 4.4%/6.7% 8%/17% 7%/9% N.A. N.A. 13%/13%
Floroscopy
time
(minutes)
N.A. N.A. N.A. N.A. N.A. 6.5/6.5 9.4 ± 2.7 24.4/22.1
Reference 12 13 15 14 11 4 5 3
CIN = contrast-induced nephropathy; SES = sirolimus-eluting stent; PES = paclitaxel-eluting stent; PCI = percutaneous coronary intervention.
results. As several millions of DES have been im-
planted worldwide since 2002 (real-world maximum
follow-up of>8 years), trials with long-term outcomes
are still warranted. In the present edition of the Journal
of Interventional Cardiology, Brown, et al. focused on
clinical outcomes up to 28months in 2,362 consecutive
patients treated with ﬁrst-generation DES.3
This registry used modern statistical techniques and
adjusted for nine different variables using a propensity
score and modeling Cox’s proportional hazard. The
overall number of patients included in the present trial
makes it the ﬁfth largest registry directly comparing
PES to SES worldwide after STENT,7 Evaluation of
Drug Eluting Stents and Ischemic Events (EVENT),8
Bern-Rotterdam,2 and Western Denmark Heart Reg-
istry9 and the second most important within the United
States. The study was performed at Dartmouth Hospi-
tal; Darthmouth Hospital was rated as one of the 30
best teaching hospitals in the United States, according
to a study concerning 971 US cardiovascular centers
carried out in 2009 by Thomson Reuters.10
What could we learn from this registry? Although
the absolute values are too low to be convincing, it
conﬁrms that no statistically signiﬁcant differences in
clinical outcome can be found between patients treated
with PES or SES (28-month mortality: PES, 4.7%;
SES, 3.8%; P < 0.05). This is factual but not new;
while most of the studies with early angiographic out-
comes and some studieswith clinical end-points during
the ﬁrst 12 months found advantages of SES over PES,
all RCTs (SORT-OUT, TAXi and SirTax) with longer
follow-up durations, and all registries except one (West-
ern Denmark Heart Registry), demonstrated similar
clinical outcomes between the two different DES.
Reality and The Intervention World
On the other hand, what is new—and more convinc-
ingly matches reality—is the occurrence of procedure-
related complications. This is crucial but seldom
disclosed information. The authors should be congrat-
ulated for their bravery. Due to patient and operator
selection, complications are rare in RCTs. In retro-
spective registries, complications are usually underes-
timated.Only prospective registries can yield valid data
regarding complications in the real world. The most
important complication rates found in the Dartmouth
HospitalDynamicRegistrywere as follows: in-hospital
mortality from 1.4–2%, periprocedural stroke rate
from 0.6%, and—more interestingly—13.2–13.5% of
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the patients developed a contrast-induced nephropathy
(CIN, deﬁned as an increase in the serum creatinine
of > 25%) with a 0.4–0.5% dialysis requirement. Is it
much? Little evidence exists on this particular subject.
CIN is highly clinically relevant and is generally as-
sociated with patient and procedural characteristics,
such as the presence of chronic renal failure, dia-
betes mellitus, or arterial hypertension, as well as the
type and amount of contrast media infused. Table 1
summarized recent studies on the incidence of CIN af-
ter coronary angiography and PCI in RCT comparing
different nonionic contrast-media and was balanced
with the amount of nonionic contrast media injected in
three different studies comparing PES to SES in unse-
lected all-comers (SORT-OUT II, TAXi and Dartmouth
Hospital Dynamic Registry). Based on studies compar-
ing nonionic contrast media, the incidence of protocol-
deﬁned CIN occurred in 7–9% of all-comers11 and 4–
24% of patients with chronic renal failure.12–15 In the
presence of important differences between the stud-
ies (type, size,% of PCI), the comparison of these re-
sults with the Dartmouth Hospital Dynamic Registry
could only be informative. Nevertheless, we should
note that in comparison with the two others SES-PES
trials that published the amount of injected contrast-
media and the duration of ﬂuoroscopy in all-comers,
the PCI recorded in the Dartmouth Hospital Dynamic
Registry appear dull: The amount of contrast used was
two times higher and the duration of ﬂuoroscopy about
three times higher than the two others studies. What
made these differences? Are they due to more complex
patients or lesions? To operators’ skills? To biases in
the registry?We are not able to answer these questions,
but the difference remains and should reinforce our
quest to strive for optimal coronary result with min-
imal complication rates. Finally, we should also ask
ourselves how real reﬂects the “real-world” described
in the present registry to our reality?
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